Free Trial

Silverback Therapeutics (SBTX) Competitors

Silverback Therapeutics logo
$9.11 -0.54 (-5.60%)
As of 10/24/2025

SBTX vs. ZYME, CALT, NLTX, AVTE, BIOA, VIRI, WHWK, SPRB, LITS, and ELYM

Should you be buying Silverback Therapeutics stock or one of its competitors? The main competitors of Silverback Therapeutics include Zymeworks (ZYME), Calliditas Therapeutics AB (publ) (CALT), Neoleukin Therapeutics (NLTX), Aerovate Therapeutics (AVTE), BioAge Labs (BIOA), Virios Therapeutics (VIRI), Whitehawk Therapeutics (WHWK), Spruce Biosciences (SPRB), Lite Strategy (LITS), and Eliem Therapeutics (ELYM).

Silverback Therapeutics vs. Its Competitors

Zymeworks (NASDAQ:ZYME) and Silverback Therapeutics (NASDAQ:SBTX) are both small-cap pharmaceutical preparations industry companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends, media sentiment and valuation.

Zymeworks has a beta of 1.51, indicating that its share price is 51% more volatile than the S&P 500. Comparatively, Silverback Therapeutics has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500.

Silverback Therapeutics has a net margin of 0.00% compared to Zymeworks' net margin of -59.96%. Zymeworks' return on equity of -21.59% beat Silverback Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Zymeworks-59.96% -21.59% -16.52%
Silverback Therapeutics N/A -29.62%-28.20%

92.9% of Zymeworks shares are held by institutional investors. Comparatively, 74.9% of Silverback Therapeutics shares are held by institutional investors. 1.9% of Zymeworks shares are held by company insiders. Comparatively, 34.4% of Silverback Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Zymeworks had 10 more articles in the media than Silverback Therapeutics. MarketBeat recorded 11 mentions for Zymeworks and 1 mentions for Silverback Therapeutics. Zymeworks' average media sentiment score of 0.28 beat Silverback Therapeutics' score of 0.00 indicating that Zymeworks is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Zymeworks
1 Very Positive mention(s)
3 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Silverback Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zymeworks
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
2 Strong Buy rating(s)
2.75
Silverback Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Silverback Therapeutics has lower revenue, but higher earnings than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than Silverback Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zymeworks$122.87M10.85-$122.69M-$0.97-18.29
Silverback TherapeuticsN/AN/A-$89.48M-$2.42-3.76

Summary

Zymeworks beats Silverback Therapeutics on 10 of the 14 factors compared between the two stocks.

Get Silverback Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SBTX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SBTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SBTX vs. The Competition

MetricSilverback TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$328.49M$1.08B$6.25B$10.67B
Dividend YieldN/A4.84%5.72%4.82%
P/E Ratio-3.761.4930.9830.65
Price / SalesN/A30.84561.02174.40
Price / CashN/A17.6337.0861.44
Price / Book1.238.0012.056.61
Net Income-$89.48M-$7.35M$3.33B$277.10M
7 Day Performance-9.35%2.49%1.89%2.55%
1 Month Performance-8.35%29.62%7.71%3.77%
1 Year Performance-38.32%-14.24%56.33%33.05%

Silverback Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SBTX
Silverback Therapeutics
N/A$9.11
-5.6%
N/A-37.3%$328.49MN/A-3.7683News Coverage
High Trading Volume
ZYME
Zymeworks
0.1682 of 5 stars
$17.93
-2.1%
N/AN/A$1.35B$76.30M-18.48460News Coverage
Analyst Forecast
CALT
Calliditas Therapeutics AB (publ)
N/A$40.00
flat
N/AN/A$1.19B$1.60B-21.62180
NLTX
Neoleukin Therapeutics
N/A$32.16
+10.8%
N/A-40.4%$302.24MN/A-10.3490Gap Up
High Trading Volume
AVTE
Aerovate Therapeutics
N/A$10.00
+6.7%
N/A-86.5%$289.85MN/A-3.3420High Trading Volume
BIOA
BioAge Labs
0.119 of 5 stars
$5.30
-1.1%
N/AN/A$190.01MN/A0.00N/A
VIRI
Virios Therapeutics
N/A$6.19
+7.5%
N/A+36.1%$119.21MN/A-22.935
WHWK
Whitehawk Therapeutics
1.3029 of 5 stars
$2.28
-14.3%
N/AN/A$107.45M$21.60M-38.0021News Coverage
Positive News
Analyst Forecast
SPRB
Spruce Biosciences
1.1042 of 5 stars
$129.54
-12.6%
$140.83
+8.7%
+203.7%$72.54M$4.91M-1.5020Trending News
Analyst Forecast
Analyst Revision
LITS
Lite Strategy
N/A$1.95
-1.5%
N/AN/A$69.53MN/A-0.41100Positive News
Analyst Forecast
ELYM
Eliem Therapeutics
N/A$2.32
+20.2%
N/A-57.2%$69.03MN/A-4.389Gap Up
High Trading Volume

Related Companies and Tools


This page (NASDAQ:SBTX) was last updated on 10/25/2025 by MarketBeat.com Staff
From Our Partners